Marksans Pharma Ltd Q3FY23 consolidated net profit at Rs. 63.40 crores

Marksans Pharma Limited has reported Consolidated financial results for the period ended December 31, 2022.

Financial Results (Q3 FY2023) - QoQ Comparison

The company has reported total income of Rs. 497.481 crores during the period ended December 31, 2022 as compared to Rs. 466.718 crores during the period ended September 30, 2022.

The company has posted net profit / (loss) of Rs. 63.408 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. 61.253 crores for the period ended September 30, 2022.

The company has reported EPS of Rs. 1.56 for the period ended December 31, 2022 as compared to Rs. 1.52 for the period ended September 30, 2022.

Financials	Q3 FY2023	Q2 FY2023	% Change
Total Income	₹497.481 crs	₹466.718 crs	6.59%
Net Profit	₹63.408 crs	₹61.253 crs	3.52%
EPS	₹1.56	₹1.52	2.63%

Financial Results (Q3 FY2023) - YoY Comparison

The company has reported total income of Rs.497.481 crores during the period ended December 31, 2022 as compared to Rs.374.690 crores during the period ended December 31, 2021.

The company has posted net profit / (loss) of Rs.63.408 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.49.121 crores for the period ended December 31, 2021.

The company has reported EPS of Rs.1.56 for the period ended December 31, 2022 as compared to Rs.1.20 for the period ended December 31, 2021.

Financials	Q3 FY2023	Q3 FY2022	% Change
Total Income	₹497.481 crs	₹374.690 crs	32.77%
Net Profit	₹63.408 crs	₹49.121 crs	29.09%
EPS	₹1.56	₹1.20	30.00%

Financial Results (9 Months Ended FY2023) - YoY Comparison

The company has reported total income of Rs.1414.467 crores during the 9 Months period ended December 31, 2022 as compared to Rs.1099.304 crores during the 9 Months period ended December 31, 2021.

The company has posted net profit / (loss) of Rs.184.376 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.156.460 crores for the 9 Months period ended December 31, 2021.

The company has reported EPS of Rs.4.54 for the 9 Months period ended December 31, 2022 as compared to Rs.3.82 for the 9 Months period ended December 31, 2021.

Financials	9 Months Ended FY2023	9 Months Ended FY2022	% Change
Total Income	₹1414.467 crs	₹1099.304 crs	28.67%
Net Profit	₹184.376 crs	₹156.460 crs	17.84%
EPS	₹4.54	₹3.82	18.85%

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 66.15 as compared to the previous close of Rs. 64.80. The total number of shares traded during the day was 420455 in over 1811 trades.

The stock hit an intraday high of Rs. 66.90 and intraday low of 64.35. The net turnover during the day was Rs. 27682432.00.

Source : Equity Bulls

Keywords

MarksansPharma Q3FY23 9MFY23 ResultUpdate